AI-driven drug developer Recursion Pharmaceuticals announced layoffs constituting approximately 20% of its workforce, equating to 160 positions, reflecting its pipeline streamlining and challenging fundraising environment in biotech. The company expects reduced cash burn and extended financial runway to Q4 2027. Recursion’s strategic focus narrows to oncology and rare diseases following its acquisition of Exscientia and recent deprioritization of multiple clinical-stage programs.